Show simple item record

dc.contributor.authorKallen, Michael E
dc.contributor.authorKoka, Rima
dc.contributor.authorSingh, Zeba N
dc.contributor.authorNing, Yi
dc.contributor.authorKocoglu, Mehmet H
dc.contributor.authorBadros, Ashraf Z
dc.contributor.authorNiyongere, Sandrine
dc.contributor.authorDuong, Vu H
dc.contributor.authorEmadi, Ashkan
dc.contributor.authorBaer, Maria R
dc.date.accessioned2022-11-22T19:10:19Z
dc.date.available2022-11-22T19:10:19Z
dc.date.issued2022-11-01
dc.identifier.urihttp://hdl.handle.net/10713/20212
dc.description.abstractNew therapies for multiple myeloma have improved outcomes, but are associated with therapy-related hematologic malignancies. We report eight patients with therapy-related B-lymphoblastic leukemias (t-B-ALL) in the setting of therapy for multiple myeloma, which included lenalidomide maintenance. A subset of patients had pancytopenia and low-level marrow involvement by acute leukemia, an unusual finding in de novo B-ALL. One patient died of chemotherapy complications; the other seven responded. No patient died of B-ALL (median follow up of 1.0 years). Our series suggests that t-B-ALL is clonally unrelated to myeloma, presents with diverse cytogenetic abnormalities, and responds well to B-ALL therapy.en_US
dc.description.urihttps://doi.org/10.1016/j.lrr.2022.100358en_US
dc.language.isoenen_US
dc.relation.ispartofLeukemia research reportsen_US
dc.rights© 2022 The Author(s).en_US
dc.subjectLenalidomideen_US
dc.subjectMelphalanen_US
dc.subjectMultiple myeloma (MM)en_US
dc.subjectTherapy-related B-lymphoblastic leukemia (t-B-ALL)en_US
dc.titleTherapy-related B-lymphoblastic leukemia after multiple myeloma.en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.lrr.2022.100358
dc.identifier.pmid36353199
dc.source.journaltitleLeukemia research reports
dc.source.volume18
dc.source.beginpage100358
dc.source.endpage
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record